ActiveSight and Serenex, Inc. announced that they have entered into a broad agreement related to protein crystallography for drug discovery. The agreement covers the co-crystallization of Serenex proprietary molecules with proteins expressed by ActiveSight. Additional details of the agreement were not disclosed.

"We are excited to expand the scope of our productive relationship with Serenex," stated Ronald V. Swanson, Ph.D., Chief Scientific Officer for ActiveSight, "their proteomics-based discovery program makes them an excellent partner for our structural biology platform."

"This agreement will enable Serenex to understand on a molecular level how its compounds bind to their targets," said Dr. Gunnar Hanson, Director of Chemistry at Serenex. "We are very pleased to work with ActiveSight and have been impressed with their technical capability."

This marks the third announced collaboration for ActiveSight.

ABOUT ACTIVESIGHT

ActiveSight, a division of Rigaku/MSC, provides high-level structural biology services to advance clients' drug discovery efforts. ActiveSight features human target proteins available for rapid co-crystallization, including Hsp90 and fructose bisphosphatase. For more information visit www.active-sight.com [1]

ABOUT SERENEX

Serenex is a chemoproteomics-based drug discovery company with a mission to develop proprietary human therapeutics that have improved likelihoods of clinical and economic success. Serenex's proprietary technologies enable the company to understand complex compound-target interactions and to discover novel compounds. To date, Serenex has lead compounds and pre-clinical programs in oncology and inflammation scheduled to enter clinical trials in early 2006. Serenex has worked with leading biotechnology and pharmaceutical companies improving their drug discovery programs in return for revenues and milestone payments. These companies include Chiron Corporation, Pfizer, Roche, Aventis and GlaxoSmithKline. For more information, visit Serenex's web site at www.serenex.com [2]